Education
About Us
Working with TipRanks
Follow Us
MannKind Corporation (MNKD)
NASDAQ:MNKD
MNKD Stock Chart & Stats
$5.91
-$0.05(-0.80%)
At close: 4:00 PM EST
$5.91
-$0.05(-0.80%)
Day’s Range― - ―
52-Week Range$3.38 - $6.51
Previous CloseN/A
Volume434.88K
Average Volume (3M)3.73M
Market Cap
$1.81B
Enterprise Value$1.91B
Total Cash (Recent Filing)$260.04M
Total Debt (Recent Filing)$225.95M
Price to Earnings (P/E)62.7
Beta0.86
Next Earnings
Mar 03, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding307,070,280
10 Day Avg. Volume3,832,513
30 Day Avg. Volume3,730,191
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)-22.39
Price to Sales (P/S)6.18
P/FCF Ratio53.77
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue6.10
Enterprise Value/Gross Profit8.11
Enterprise Value/Ebitda26.16
Forecast
1Y Price Target
$9.67Price Target Upside63.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Afrezza Dosing Label UpdateAnalyst emphasizes that an updated dosing conversion on the Afrezza label should improve dosing accuracy and make it easier for patients using injections or pumps to switch to inhaled insulin.
Autoinjector Regulatory AdvancementAnalyst highlights that FDA acceptance of the Furoscix autoinjector application and anticipated partner clinical readouts could broaden clinical use of the diuretic and materially expand the addressable market and cash flow potential.
Pediatric Label ExpansionAnalyst notes that an approved pediatric label for Afrezza could open access to pediatric insulin patients and substantially increase the product's addressable market and revenue potential.
Bears Say
Clinical Program DiscontinuationAnalyst reports that discontinuation of the MNKD‑101 trial for nebulized clofazimine due to futility removes a potential development asset and reduces pipeline optionality and future revenue prospects.
Execution And Partner RiskAnalyst flags commercial execution difficulties, clinical trial failures, regulatory setbacks, and reliance on a commercialization partner as key risks that could limit revenue realization.
Under‑dosing Efficacy ReportsReal‑world reports linking Afrezza's perceived lack of efficacy to under‑dosing underscore the need for clearer dosing guidance and could slow adoption if not resolved.
MannKind News
MNKD FAQ
What was MannKind Corporation’s price range in the past 12 months?
MannKind Corporation lowest stock price was $3.38 and its highest was $6.51 in the past 12 months.
What is MannKind Corporation’s market cap?
MannKind Corporation’s market cap is $1.81B.
When is MannKind Corporation’s upcoming earnings report date?
MannKind Corporation’s upcoming earnings report date is Mar 03, 2026 which is in 19 days.
How were MannKind Corporation’s earnings last quarter?
MannKind Corporation released its earnings results on Nov 05, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.011.
Is MannKind Corporation overvalued?
According to Wall Street analysts MannKind Corporation’s price is currently Undervalued.
Does MannKind Corporation pay dividends?
MannKind Corporation does not currently pay dividends.
What is MannKind Corporation’s EPS estimate?
MannKind Corporation’s EPS estimate is 0.02.
How many shares outstanding does MannKind Corporation have?
MannKind Corporation has 307,070,280 shares outstanding.
What happened to MannKind Corporation’s price movement after its last earnings report?
MannKind Corporation reported an EPS of $0.03 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went up 10.584%.
Which hedge fund is a major shareholder of MannKind Corporation?
Currently, no hedge funds are holding shares in MNKD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MannKind Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (63.62% Upside)
$9.67 (63.62% Upside)
Blogger Sentiment
Bullish
MNKD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 240.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.7%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
4.97%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.56%
Trailing 12-Months
Company Description
MannKind Corporation
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect cells against inflammatory conditions. MannKind Corporation was incorporated in 1991 and is headquartered in Westlake Village, California.
MNKD Company Deck
MNKD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance driven by Tyvaso DPI and Afrezza, alongside strategic growth initiatives such as the acquisition of scPharmaceuticals. However, challenges such as a decline in VGo revenue and increased SG&A expenses were noted. Overall, the positive aspects of revenue growth and strategic acquisitions outweighed the lowlights.View all MNKD earnings summariesMNKD Stock 12 Month Forecast
Average Price Target
$9.67
▲(63.62% Upside)
Technical Analysis
Ownership Overview
2.92% Insiders
10.93% Mutual Funds
0.97% Other Institutional Investors
69.20% Public Companies and Individual Investors